Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Titel:
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Auteur:
San-Miguel, Jesús F Hungria, Vânia T M Yoon, Sung-Soo Beksac, Meral Dimopoulos, Meletios Athanasios Elghandour, Ashraf Jedrzejczak, Wieslaw Wiktor Günther, Andreas Nakorn, Thanyaphong Na Siritanaratkul, Noppadol Corradini, Paolo Chuncharunee, Suporn Lee, Je-Jung Schlossman, Robert L Shelekhova, Tatiana Yong, Kwee Tan, Daryl Numbenjapon, Tontanai Cavenagh, Jamie D Hou, Jian LeBlanc, Richard Nahi, Hareth Qiu, Lugui Salwender, Hans Pulini, Stefano Moreau, Philippe Warzocha, Krzysztof White, Darrell Bladé, Joan Chen, WenMing de la Rubia, Javier Gimsing, Peter Lonial, Sagar Kaufman, Jonathan L Ocio, Enrique M Veskovski, Ljupco Sohn, Sang Kyun Wang, Ming-Chung Lee, Jae Hoon Einsele, Hermann Sopala, Monika Corrado, Claudia Bengoudifa, Bourras-Rezki Binlich, Florence Richardson, Paul G